New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 13, 2012
08:31 EDTMDVNMedivation, Astellas XTANDI available to those previously treated with Docetaxel
Medivation and Astellas Pharma announced the availability of XTANDI capsules for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI was approved by the U.S. FDA on Aug. 31, 2012. XTANDI is being distributed through a network of specialty pharmacies and specialty distributors.
News For MDVN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
07:06 EDTMDVNAmerican Society of Clinical Oncology to hold annual meeting
Subscribe for More Information
May 28, 2015
09:00 EDTMDVNPfizer has 'significant capacity' for additional deals, says JPMorgan
Subscribe for More Information
May 17, 2015
12:53 EDTMDVNMedivation, Astellas report enzalutamide study met primary endpoint
Subscribe for More Information
May 15, 2015
07:35 EDTMDVNMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use